Author | Susan A. Melin, MD


Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer

May 02, 2002

ByA. William Blackstock, Jr, MD|Susan A. Melin, MD|Jerome M. Butler, MD|Suzanne Patton, MD|Benjamin Pineau, MD|David Albertson, MD|Russell Howerton, MD|Edward Levine, MD

Early clinical studies combining irinotecan (CPT-11, Camptosar) and gemcitabine (Gemzar) have yielded encouraging results. Gemcitabine administered via a twice-weekly schedule results in an enhanced radiation-sensitizing effect.